Clinical trial NCT03500224: A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male Participants
Official title: A Phase 1, Open-label, Single Intravenous Infusion Dose Study to Evaluate the Mass Balance, Pharmacokinetics, Metabolism, and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Adult Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Keywords: Drug therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2018-04-18
Enrollment: 6
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose of this study is to determine the mass balance, routes of elimination and characterize the metabolic profiles of a single intravenous dose of \[14C\]-TAK-954, identify major circulating and excreted metabolites. This study will also determine the single-dose PK of total radioactivity, TAK-954 and its metabolites where possible.

Detailed description: The drug being tested in this study is called TAK-954. This study will assess the mass balance, metabolic profiles and routes of elimination of single intravenous dose of \[14C\]-TAK-954, and will determine the major circulating and excreted metabolites and single-dose PK of total radioactivity, TAK-954, THRX513466, and THRX 913682 in healthy male participants.

The study will enroll approximately 6 participants. All participants will receive a single dose of \[14C\]-TAK-954 0.5 mg on Day 1.

This single-center trial will be conducted in Netherlands. The overall time to participate in this study is approximately 6 to 7 weeks. Participants will make a final visit to the clinic 15 days after last dose of study drug for a follow-up assessment.

Eligibility criteria: Inclusion Criteria:

1. Be a man aged 18 to 55 years, inclusive, at the screening visit.
2. Have a body mass index (BMI) greater than or equal to (\>=) 18 and less than or equal to (\<=) 30 kilogram per square meter (kg/m\^2) and a body weight greater than (\>) 50 kilogram (kg) at the screening visit.
3. Be a nonsmoker who has not used tobacco- or nicotine-containing products (example, nicotine patch) for at least 6 months before administration of the initial dose of trial drug.
4. Meet the following birth control requirements:

   * Is a male participant who is sterile or agrees to use an appropriate method of contraception, including a condom, from the first dose of study drug until 30 days after the last dose of study drug. No restrictions are required for a vasectomized male participant provided that the participant is at least 1 year postbilateral vasectomy procedure before the first dose of study drug. A male participant whose vasectomy procedure was performed less than 1 year before the first dose of study drug must follow the same restrictions as a nonvasectomized man. Appropriate documentation of surgical procedures should be provided.
   * Is a male participant who agrees to not donate sperm from trial drug administration on the first day of the first dose until 30 days after the last dose of study drug.

Exclusion Criteria:

1. Has total 14C radioactivity measured by accelerator mass spectrometry in plasma (during screening) exceeding 14C/12C ratio 1.1E-12.
2. Participated in any study with a radiation dose above 0.1 millibecquerel (MBq) or radiation burden above 0.1 millisievert (mSv) within 1 year before screening.
3. Was exposed to significant radiation (example, serial x-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring) within 12 months before check-in.
4. Irregular defecation pattern (less than once per 2 days).
5. Has a history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to beer 354 milliliter \[mL\]/12 ounce \[oz\], wine 118 mL/4 oz, or distilled spirits 29.5 mL/1 oz).
6. Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.
7. Has a substance abuse disorder.

Primary outcomes:
measure: Cumulative Percentage of Administered Radioactivity Recovered in Urine
timeFrame: Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose
measure: Cumulative Percentage of Administered Radioactivity Recovered in Feces
timeFrame: Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose
measure: Cumulative Percentage of Radioactivity in Urine and Feces Combined
timeFrame: Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose
measure: Normalized Recovery as Percentage of Dose for TAK-954 and TAK-954 Metabolites in Urine and Feces Combined
timeFrame: Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose
measure: Normalized Recovery as Percentage of Dose for TAK-954 and TAK-954 Metabolites in Urine
timeFrame: Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose
measure: Normalized Recovery as Percentage of Dose for TAK-954 and TAK-954 Metabolites in Feces
timeFrame: Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose
measure: Mean Percent of Total Radioactivity in Plasma for TAK-954 and TAK-954 Metabolites
timeFrame: Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose
measure: Cumulative Percentage of Dose Excreted in Urine for TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose
measure: Cumulative Percentage of Dose Excreted in Feces for TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose
measure: Mean Concentration of Total Radioactivity in Whole Blood and Plasma [14C]-TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Cmax: Maximum Observed Plasma and Whole Blood Concentrations of Radioactivity for [14C]-TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Cmax: Maximum Observed Plasma Concentration for TAK-954 and TAK-954 Metabolites
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: AUClast: Area Under the Plasma and Whole Blood Radioactivity-time Curve From Time 0 to the Time of the Last Quantifiable Radioactivity for [14C]-TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954 and TAK-954 Metabolites
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: AUC∞: Area Under the Plasma and Whole Blood Radioactivity-time Curve From Time 0 to Infinity for [14C]-TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954 and TAK-954 Metabolites
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Tmax: Time to Reach the Maximum Plasma and Whole Blood Radioactivity for [14C]-TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-954 and TAK-954 Metabolites
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: t1/2z: Terminal Disposition Phase Half-life of Radioactivity in Plasma and Whole Blood for [14C]-TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: t1/2z: Terminal Disposition Phase Half-life in Plasma for TAK-954 and TAK-954 Metabolites
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: CL: Total Clearance After Intravenous Administration for [14C]-TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: CL: Total Clearance of TAK-954 After Intravenous Administration of [14C]-TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Vz: Volume of Distribution During the Terminal Disposition Phase After Intravenous Administration for [14C]-TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Vz: Volume of Distribution During the Terminal Disposition Phase After Intravenous Administration for TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Aet Urine: Amount of Total Radioactivity Excreted in Urine From Time 0 to Time t for [14C]-TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Aet Urine: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Aet Feces: Amount of Total Radioactivity Excreted in Feces From Time 0 to Time t for [14C]-TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Fet Urine: Fraction of Drug Excreted in Urine From Time 0 to Time t for TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Fet Urine: Fraction of Total Radioactivity Excreted in Urine From Time 0 to Time t for [14C]-TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Fet Feces: Fraction of Radioactivity Excreted in Feces From Time 0 to Time t for [14C]-TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Secondary outcomes:
measure: Ratio of Total Radioactivity in Whole Blood to Plasma
timeFrame: Day 1 pre-dose and at multiple time points (up to 264 hours) post-dose
measure: Ratio of AUC∞: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954 to Total Radioactivity in Plasma TAK-954
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE)
timeFrame: Baseline up to Day 31
measure: Percentage of Participants With Adverse Events (AEs) Leading to Discontinuation of [14C]-TAK-954
timeFrame: Baseline up to Day 15
Other outcomes:
Locations:
city: Groningen
country: Netherlands
facility: PRAHS
Study officials:
affiliation: Millennium Pharmaceuticals, Inc.
name: Medical Director
role: STUDY_DIRECTOR
References: